A phase 2 multi-center, randomized, placebo-controlled clinical trial assessing XW003 for the treatment of type 2 diabetes mellitus

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Aug 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Jun 2023 Results presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
23 Jun 2023 According to a Sciwind Biosciences media release, highlight of clinical data for Ecnoglutide (XW003) from this clinical study will be presented at the American Diabetes Association (ADA) 83rd Annual Conference. The ADA conference is being held in San Diego, CA, June 23-26, 2023.
02 Aug 2022 According to a Sciwind Biosciences media release, Dalong Zhu, MD, Professor of Nanjing Drum Tower Hospital, is principal investigator of this study

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com